BFRI Biofrontera Inc

$BFRI I am going to wake up one day soon and see this over 2. There are so many bios out there without a product, much less a product FDA-approved to treat cancer. Yet this one is dragged over a few more shares in the bucket. I get it. That's how markets work. If the company can execute on the new label, anyone in under 2 will get paid.

$BFRI I am thinking many here will be looking back at this day and asking ourselves “Remember that one day in mid September just one day after official approval of a drug that dermatologists are already using for another indication that the stock price plummeted despite the company finally having a strong path to financial success. Why didn’t I add a ton?” I won’t be asking that because I am adding a ton today.

$BFRI "Basal cell carcinoma (BCC) is the most common skin cancer in the United States, with approximately 3.6 million cases diagnosed annually, according to the Skin Cancer Foundation. Published estimates suggest that the superficial subtype accounts for approximately 15%-20% of BCC cases, or an estimated 540,000 to 720,000 sBCC cases annually in the U.S.2. Superficial BCC lesions can be up to several cm in diameter and are frequently located on the trunk and extremities and often present as multiple lesions, for which non-surgical, tissue-sparing treatment options are limited." ---GlobeNewswire

$BFRI Loading the boat here - and loading up heavily. If they dilute, I’ll be averaging down substantially. Let’s see where this takes us over the next 12–18 months. $NRXP holding 8k shares but will at least tripple the position today. Those are exciting times. No risk no fun - nothing is guaranteed, but the setup looks great to me.

$BFRI I hope no one is short on the next quarterly announcement and the next three or you will be sorry. This is going to blow through the roof as we all know it is a viable company now and they have an existing network of clients to feed from and now with approvals they are gold.

$BFRI "The approval is supported by a multicenter, randomized, double-blind, vehicle-controlled Phase 3 trial in 187 adults with histologically confirmed sBCC. The primary endpoint was a composite of both clinical and histological complete response of a main target lesion 12 weeks after the start of the last PDT cycle. This rigorous target was achieved in 66% of subjects treated with Ameluz PDT (95/145) compared with 5% of subjects treated with placebo-PDT (2/42). Histological clearance of the main target lesion was seen in 76% of Ameluz PDT treated patients versus 19% with Placebo-PDT, and 83% of Ameluz-treated subjects achieved complete clinical clearance of all target lesions compared with 21% for Placebo-PDT. The most common adverse reactions were application-site reactions consistent with the known safety profile of Ameluz PDT." ---GlobeNewswire

$BFRI welp. I guess I'll average down. Lol. At least it's a real company with a real product.

$BFRI this one is. A steal rn- MILLIONS of fair skinned boomers who grew up using no sunscreen- will need this company…all covered by Medicare

$BFRI I SOLD TODAY 100 k shares… I was here 5 years. I know what Patient means. I lost here more than 330 k. There are now a lot of opportunities in market. My last big mistake it was no selling yesterday. A lot of opportunities I lost in the last 5 years being here. BFRI is today in the best moment. Probably will hit 3 dollars soon, but I prefer to invest in others stronger that today are also very cheap. The best to everyone here.

$BFRI Y'all humor me for a second. Okay, they have 30 consecutive business days of trading under a dollar before getting a notice. To which they have 180 days after that to get back to above a dollar. Isn't it interesting that they went under a dollar yesterday Oct 5th to which 30 business days would put them at Nov 16-18th. Their Q3 which is the worst revenue wise due to the seasonal sump of summer is Nov. 11-13th (maybe). Heck it can even fall on Nov 16th. Therefore, they could get hit with doubt bad news within weeks of each other. Then 180 days from that is Saturday, May 15, 2027. Q1 for them this year was May 14th. Coincidence i think not, something is up and they are trying to give them little to no wiggle room. The thing that will help them is for everything to go right and Q4 is amazing. I just found that to be interesting and this could be completely a nothingburger post.

$BFRI tempted to get in but im cooked with FDA approved $OTLK also, approving just make ppl lose money lol.

$BFRI how has this not moved an cancer drug FDA approval $MRNA doubled on hints of cancer drug approval

$BFRI stock is cheap untill it isn't. If I have learned one thing in my 22 years of investing: if fundamentals are in line, the big reward will come.

$BFRI Can't wait for this whole dilution scare that might not even happen to pass, and we can get on with the stock moving up as it should.

$BFRI 12% of U.S. Ameluz revenue when annual U.S. sales are ≤ $65M and 15% when annual U.S. Ameluz revenue exceeds $65M…. Obviously someone (BFRI AG) sees BFRI being worth 65m or more in rev… BFRI owns Biofrontera Discovery GmbH in Germany. Discovery is essentially the scientific/clinical/R&D backbone for BFRI. The FDA approval is only Catalyst 1 BFRI’s own research page currently lists: 1. Ameluz — sBCC 2. Ameluz — AK trunk/extremities 3. Ameluz — larger treatment area 4. Ameluz — acne 5. new formulation 6. reduced-pain PDT 7. SCC in situ 8. RhodoLED platform development.

$BFRI the time is coming. Anyone who’s fresh, if you’ve got 6 months to spare and money to keep investing this isn’t a bad place to wait . NFA All it takes is that 1 earnings (hopefully Q4) To set the tone and confirm they no longer are looking for cash to operate. Dilution being an eliminated fear will drive lots and lots of new pockets to start their position. That’s when the fun only begins.

$BFRI on the way to a double digit stock! News flow is excellent…and be visible qoq and yoy!

$BFRI everybody who now sells for pennies is an idiot! No doubt about that. Breakeven on the horizon.

$BFRI fully dilluted market cap according to chatgpt is 30 million. Revenue runrate is @ 48 million. @ 52 million breakeven.

$BFRI the only fear is cash….nothing else about the company is bad besides the balance sheet and even that is improving…just not there quite yet. Q3 is around the corner and should give us a bounce back if guidance is good and profitability continued in 2026!